CCL2 and metabolic dysfunction-associated steatohepatitis: In our study, CCL2 significantly correlated with the severity of human NASH and CCL2 release from ECs was significantly altered by RUNX1 expression, adding novel insight into how RUNX1/CCL2 mediates infiltration of inflammatory cells and angiogenesis in NASH.